Natriuretic peptides in heart failure: should therapy be guided by BNP levels?

[1]  M. McCarthy,et al.  Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. , 2007, Human molecular genetics.

[2]  A. Dobson,et al.  How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review , 2005, BMJ : British Medical Journal.

[3]  A. Cohen-Solal,et al.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.

[4]  M. Kinoshita,et al.  Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[5]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[6]  J. Cohn,et al.  Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT) , 2002, Circulation.

[7]  C. Yancy,et al.  Influence of hospital length of stay for heart failure on quality of care. , 2008, The American journal of cardiology.

[8]  L. Newby,et al.  National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. , 2008, Clinical biochemistry.

[9]  Faquan Liang,et al.  Evidence for functional heterogeneity of circulating B-type natriuretic peptide. , 2007, Journal of the American College of Cardiology.

[10]  D. Levy,et al.  Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure , 2009, Nature Genetics.

[11]  D. Levy,et al.  Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.

[12]  Harlan M Krumholz,et al.  ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society , 2005, Circulation.

[13]  N. Freemantle,et al.  Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial. , 2008, Journal of the American College of Cardiology.

[14]  Kenji Nakamura,et al.  Cardiac fibrosis in mice lacking brain natriuretic peptide. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Robert H Christenson,et al.  National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. , 2007, Circulation.

[16]  A. Struthers,et al.  Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction , 1993, The Lancet.

[17]  H. S. Kim,et al.  Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[19]  G. Palade,et al.  SPECIFIC GRANULES IN ATRIAL MUSCLE CELLS , 1964, The Journal of cell biology.

[20]  J. P. Henry,et al.  Evidence of the Atrial Location of Receptors Influencing Urine Flow , 1956, Circulation research.

[21]  D. Lloyd‐Jones,et al.  Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. , 2006, Journal of the American College of Cardiology.

[22]  Michael L. Johnson,et al.  Deconvolution Analysis of Cardiac Natriuretic Peptides During Acute Volume Overload , 2000, Hypertension.

[23]  S. Réhman,et al.  Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[24]  R. Doughty,et al.  Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 1999, Circulation.

[25]  D. Levy,et al.  Impact of age and sex on plasma natriuretic peptide levels in healthy adults. , 2002, The American journal of cardiology.

[26]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[27]  E. Braunwald,et al.  Natriuretic peptides in heart failure: should therapy be guided by BNP levels? , 2010, Nature Reviews Cardiology.

[28]  J. Rouleau,et al.  Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial , 2004, Circulation.

[29]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[30]  A. Richards,et al.  Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. , 1993, British heart journal.

[31]  M. Cheitlin,et al.  BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial , 2010 .

[32]  C. Frampton,et al.  Abstract 5946: Ntprobnp Guided Treatment for Chronic Heart Failure: Results from the Battlescarred Trial , 2008 .

[33]  Naoto Minamino,et al.  A new natriuretic peptide in porcine brain , 1988, Nature.

[34]  R. Califf,et al.  Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. , 2005, American heart journal.

[35]  M. Pfeffer,et al.  Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. , 2007, Journal of the American College of Cardiology.

[36]  C. Yancy,et al.  Use of aldosterone antagonists in heart failure. , 2009, JAMA.

[37]  M. Emi,et al.  Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels. , 2007, Biochemical and biophysical research communications.

[38]  Gabriel Thabut,et al.  Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. , 2004, Journal of the American College of Cardiology.

[39]  O. Vuolteenaho,et al.  B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. , 1998, Annals of medicine.

[40]  A. Ferreira,et al.  N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.

[41]  C. Frampton,et al.  Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure , 2006, Circulation.

[42]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[43]  P. Twomey,et al.  Using the single-compartment ratio model to calculate half-life, NT-proBNP as an example. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[44]  E. Hartter,et al.  Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[45]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.

[46]  R. Doughty,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 2001, Journal of the American College of Cardiology.

[47]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[48]  Moĭbenko Aa,et al.  The heart as an endocrine organ , 1990 .

[49]  J. Cohn,et al.  Valsartan in heart failure trial (Val-HeFT) , 1998 .